Kintara Therapeutics, Inc. (KTRA)
Stock Price:
$1.51 USD
0.01 (0.67%)
Updated Oct 23, 2020 12:39 PM EDT - Market open
Key Info
| Market Cap |
35.55M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-9.13M |
| Shares Out |
23.54M |
| EPS (ttm) |
-0.87 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$1.51 |
| Previous Close |
$1.50 |
| Change ($) |
0.01 |
| Change (%) |
0.67% |
| Day's Open |
1.46 |
| Day's Range |
1.43 - 1.55 |
| Day's Volume |
284,958 |
| 52-Week Range |
0.38 - 1.95 |
More Stats
| Market Cap |
35.55M |
| Enterprise Value |
33.16M |
| Earnings Date (est) |
Nov 16, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
23.54M |
| Float |
19.38M |
| EPS (basic) |
-0.87 |
| EPS (diluted) |
-0.87 |
| FCF / Share |
-0.76 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
271,216 |
| Short Ratio |
0.48 |
| Short % of Float |
1.40% |
| Beta |
2.08 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
11.02 |
| Revenue |
n/a |
| Operating Income |
-9.20M |
| Net Income |
-9.13M |
| Free Cash Flow |
-7.93M |
| Net Cash |
2.39M |
| Net Cash / Share |
0.10 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-145.95% |
| ROE |
-818.20% |
| ROIC |
688.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.25*
(181.46% upside)
Low
3.00
Current: $1.51
High
6.00
Target: 4.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -9.20 | -8.40 | -11.17 | -8.32 | -6.21 | -4.72 | 5.25 | -6.29 | -2.71 | -1.29 |
| Net Income | -9.13 | -8.05 | -11.14 | -8.08 | -8.86 | -4.35 | -6.36 | -8.29 | -2.40 | -1.33 |
| Shares Outstanding | 10.44 | 2.57 | 2.09 | 1.20 | 1.09 | 0.95 | 0.80 | 0.74 | 0.33 | 0.21 |
| Earnings Per Share | -0.87 | -3.16 | -5.42 | -7.40 | -8.30 | -4.60 | - | -11.20 | -7.20 | -6.40 |
| Operating Cash Flow | -7.93 | -6.33 | -9.85 | -8.02 | -5.15 | -3.85 | -4.00 | -5.52 | -0.58 | -0.23 |
| Capital Expenditures | - | - | -0.01 | -0.02 | -0.02 | - | - | - | - | - |
| Free Cash Flow | -7.93 | -6.33 | -9.86 | -8.04 | -5.16 | -3.85 | -4.00 | -5.52 | -0.58 | -0.23 |
| Cash & Equivalents | 2.39 | 3.72 | 5.97 | 6.59 | 6.16 | 1.75 | 4.76 | 4.14 | 0.02 | 0.00 |
| Total Debt | - | - | - | - | - | - | 0.28 | 0.27 | 0.26 | - |
| Net Cash / Debt | 2.39 | 3.72 | 5.97 | 6.59 | 6.16 | 1.75 | 4.48 | 3.86 | -0.25 | 0.00 |
| Assets | 2.94 | 4.04 | 7.07 | 7.91 | 6.36 | 2.58 | 5.00 | 4.32 | 0.18 | - |
| Liabilities | 2.67 | 2.07 | 1.64 | 1.33 | 1.50 | 3.40 | 5.91 | 5.14 | 1.51 | - |
| Book Value | 0.26 | 1.97 | 5.44 | 6.58 | 4.86 | -0.82 | -0.90 | -0.82 | -1.33 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Kintara Therapeutics, Inc. |
| Country |
United States |
| Employees |
4 |
| CEO |
Saiid Zarrabian |
Stock Information
| Ticker Symbol |
KTRA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KTRA |
Description
Kintara Therapeutics, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.